pre activity survey

Release Date: Wed., December 11, 2013

Expiration Date: Thurs., December 11, 2014

Educational Overview
The pandemic of multidrug-resistant (MDR) bacteria and their continuing spread is beyond dispute, and is now considered a global public crisis. The threat of infections caused by MDR organisms has been well documented over the past decade along with warnings concerning the consequences of inappropriate use of antimicrobials in accelerating resistance development. The newest threat includes the emergence and spread of carbapenem-resistant Enterobacteriaceae.

Clinicians must consider all aspects when designing a treatment plan for combating MDR infections. Inappropriate initial therapy can have significant consequences with respect to patient morbidity, mortality, and overall costs. Therefore, clinicians must utilize the latest strategies in infection control, diagnostics, and antibiotic selection with regimens optimized to ensure the highest probability of achieving a successful outcome. With few effective agents available, there is a pressing need for new management strategies when combating serious bacterial infections. Optimizing antimicrobial therapy based on patient-related, pathogen-related, and drug-related factors is essential in maximizing the probability of successful outcomes.

Target Audience
Optimal management of serious bacterial infections in hospital setting requires an interdisciplinary approach that includes all HCPs involved in the management of patients with or at risk for these infections. Therefore, this continuing medical education activity will target HCPs at the forefront of diagnosing, managing, and preventing infections at healthcare institutions. These include ID specialists, infection control specialists, hospital epidemiologists, clinical microbiologists, and clinical pharmacists.

Learning Objectives
Healthcare professionals participating in this educational activity will be able at its conclusion to:

  1. Evaluate the utility of the latest assays and techniques for diagnosing bacterial infections to guide infection control and treatment decisions
  2. Differentiate new and emerging therapeutic options for treating multidrug-resistant bacterial infections
  3. Identify strategies to optimize the use of antimicrobials by considering patient-, pathogen-, and drug-related factors



Educational Format
These Online Presentations are based on the CME/CPE Satellite Symposium which was held at ICAAC 2013.

Please Note: If you have received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version.

This online activity is divided into four portable and easy to access episodes:


MDR Bacteria – What Can Be Done

George G. Zhanel, PharmD, PhD FCCP

Latest Approaches to Address the Challenge:
From Infection Control to Diagnostics

John Segreti, MD

Optimizing Antimicrobial Use to Improve Outcomes

Jason Gallagher,PharmD, BCPS

Knowing the Armamentarium for Difficult Bacterial Infections

George G. Zhanel, PharmD, PhD FCCP



George G. Zhanel, PharmD, PhD FCCP
Department of Medical Microbiology and Infectious Diseases
Faculty of Medicine, University of Manitoba

Canadian Antimicrobial Resistance Alliance (CARA)
Winnipeg, Canada

John Segreti, MD
Professor of Medicine, Section of Infectious Diseases
Rush University Medical Center

Chicago, IL
Jason C. Gallagher, PharmD, BCPS
Clinical Professor
Clinical Specialist, Infectious Diseases
Director, Infectious Diseases Pharmacotherapy Residency
Temple University



This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Center for Independent Healthcare Education and Vemco MedEd, LLC. Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center for Independent Healthcare Education designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity.

ACPE UAN:  0473-9999-13-018-H01-P
Activity type: Knowledge-based

For questions regarding accreditation, please contact


Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review each episode.
  3. Complete the Online Post Test, Evaluation, and Credit Application form (
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.
  6. Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit


In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Planning Committee Members
Jason C. Gallagher, PharmD
John Segreti, MD
George G. Zhanel, PharmD, PhD
Paul DeLisle
Marco Cicero, PhD
Maja Drenovac, PharmD, CCMEP




Jason C. Gallagher, PharmD, BCPS (Faculty/Planner) has relevant financial relationships with commercial interest as follows:

  • Advisory Board: Optimer Pharmaceuticals, Trius Therapeutics
  • Grant Recipient/Research Support: Merck
  • Speakers Bureau: Astellas Pharma US, Forest Laboratories, Optimer Pharmaceuticals

Dr. Gallagher does not discuss the off-label use of a product.

John Segreti, MD (Faculty/Planner) has relevant financial relationships with commercial interests as follows:

  • Consultant: Merck & Co. and Biomets
  • Shareholder: Pfizer
  • Speakers Bureau: Merck & Co.

Dr. Segreti does not discuss the off-label use of a product.

George G. Zhanel, PharmD, PhD (Faculty/Planner) has relevant financial relationships with commercial interests as follows:

  • Grant Recipient/Research Support: AstraZeneca, Cerexa, Cubist Pharmaceuticals, Forest Laboratories, Optimer Pharmaceuticals, The Medicines Company, Merck & Co., Pfizer, Triton, Trius Therapeutics,

Dr. Zhanel discusses the off-label uses of the following products: tedizolid, cadazolid, radezolid, solithromycin, ceftolozane/tazobactam, ceftazidime/avibactam, ceftaroline/avibactam, oritavancin, high dose daptomycin, eravacycline, plazomicin, ceftobiprole, imipenem, MK7655.

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. No other speakers or authors will discuss off-label use of a product.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Joint Sponsorship
This activity is jointly sponsored by
Center for Independent Healthcare Education and Vemco MedEd.


Commercial Support
This activity is supported by an educational grant from Forest Laboratories.



There is no fee to participate in this activity.

 Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2013-2014 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy



By clicking on an Episode below, I acknowledge that I have read the entire CME information.


Post Test
Course Material